Among patients with tumours that overexpressed human epidermal growth factor receptor 2 (her2/neu), 17% achieved pcr as compared with 25% of patients with non-overexpressing tumours; only 1 patient had received trastuzumab. The gene discussed is ERBB2; the disease is neoplasm.